Concepts (174)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Kidney Transplantation | 9 | 2024 | 120 | 3.450 |
Why?
|
| Cytomegalovirus Infections | 6 | 2022 | 28 | 3.180 |
Why?
|
| Cytomegalovirus | 4 | 2022 | 14 | 1.450 |
Why?
|
| Transplant Recipients | 6 | 2023 | 20 | 1.200 |
Why?
|
| HIV Infections | 6 | 2024 | 457 | 1.130 |
Why?
|
| Opportunistic Infections | 2 | 2017 | 7 | 1.060 |
Why?
|
| Methicillin-Resistant Staphylococcus aureus | 2 | 2022 | 107 | 1.040 |
Why?
|
| Retrospective Studies | 14 | 2023 | 3220 | 0.990 |
Why?
|
| Inpatients | 4 | 2023 | 132 | 0.980 |
Why?
|
| Graft Rejection | 5 | 2024 | 63 | 0.930 |
Why?
|
| Daptomycin | 1 | 2022 | 7 | 0.820 |
Why?
|
| Anti-Infective Agents | 1 | 2022 | 33 | 0.800 |
Why?
|
| Staphylococcal Infections | 2 | 2016 | 144 | 0.790 |
Why?
|
| Cross Infection | 1 | 2023 | 253 | 0.730 |
Why?
|
| Organ Transplantation | 2 | 2018 | 22 | 0.720 |
Why?
|
| Hypoglycemia | 1 | 2020 | 13 | 0.710 |
Why?
|
| Hypoglycemic Agents | 1 | 2020 | 35 | 0.700 |
Why?
|
| Quality Indicators, Health Care | 1 | 2020 | 35 | 0.690 |
Why?
|
| Antifungal Agents | 2 | 2018 | 43 | 0.690 |
Why?
|
| Antiviral Agents | 2 | 2022 | 66 | 0.690 |
Why?
|
| Electronic Health Records | 1 | 2020 | 72 | 0.680 |
Why?
|
| Adult | 14 | 2022 | 7336 | 0.670 |
Why?
|
| Humans | 28 | 2024 | 25692 | 0.630 |
Why?
|
| Lung Transplantation | 2 | 2016 | 12 | 0.630 |
Why?
|
| United States | 8 | 2022 | 1943 | 0.630 |
Why?
|
| Cryptococcosis | 1 | 2018 | 5 | 0.600 |
Why?
|
| Population Health | 1 | 2018 | 4 | 0.600 |
Why?
|
| Consensus | 1 | 2018 | 90 | 0.580 |
Why?
|
| Ustilaginales | 1 | 2017 | 1 | 0.560 |
Why?
|
| Yeasts | 1 | 2017 | 3 | 0.560 |
Why?
|
| Dermatomycoses | 1 | 2017 | 2 | 0.560 |
Why?
|
| Fungemia | 1 | 2017 | 8 | 0.560 |
Why?
|
| Exanthema | 1 | 2017 | 12 | 0.560 |
Why?
|
| Staphylococcus lugdunensis | 1 | 2016 | 1 | 0.550 |
Why?
|
| Endocarditis, Bacterial | 1 | 2016 | 10 | 0.540 |
Why?
|
| Patient Readmission | 2 | 2015 | 116 | 0.540 |
Why?
|
| Middle Aged | 13 | 2024 | 8403 | 0.520 |
Why?
|
| Bacteremia | 1 | 2016 | 94 | 0.510 |
Why?
|
| Risk Factors | 7 | 2022 | 2224 | 0.500 |
Why?
|
| Renal Insufficiency | 1 | 2014 | 13 | 0.480 |
Why?
|
| Heart Transplantation | 1 | 2014 | 29 | 0.470 |
Why?
|
| International Classification of Diseases | 1 | 2014 | 12 | 0.470 |
Why?
|
| Male | 16 | 2024 | 13917 | 0.460 |
Why?
|
| Anti-Bacterial Agents | 3 | 2023 | 333 | 0.460 |
Why?
|
| Pneumonia, Viral | 1 | 2015 | 80 | 0.440 |
Why?
|
| Tissue and Organ Procurement | 2 | 2024 | 24 | 0.400 |
Why?
|
| Aged | 8 | 2022 | 8501 | 0.400 |
Why?
|
| Immunocompromised Host | 3 | 2017 | 39 | 0.390 |
Why?
|
| Young Adult | 6 | 2021 | 1855 | 0.380 |
Why?
|
| Postoperative Complications | 2 | 2024 | 827 | 0.380 |
Why?
|
| Lemierre Syndrome | 1 | 2011 | 1 | 0.370 |
Why?
|
| Graft Survival | 4 | 2024 | 92 | 0.370 |
Why?
|
| Tissue Donors | 4 | 2024 | 61 | 0.370 |
Why?
|
| Incidence | 3 | 2021 | 731 | 0.360 |
Why?
|
| Kidney Failure, Chronic | 2 | 2024 | 148 | 0.320 |
Why?
|
| Female | 12 | 2024 | 14273 | 0.320 |
Why?
|
| Time Factors | 4 | 2016 | 1336 | 0.300 |
Why?
|
| Databases, Factual | 2 | 2021 | 329 | 0.280 |
Why?
|
| Directly Observed Therapy | 1 | 2006 | 2 | 0.270 |
Why?
|
| Antiretroviral Therapy, Highly Active | 1 | 2006 | 60 | 0.260 |
Why?
|
| HIV Seropositivity | 1 | 2006 | 49 | 0.260 |
Why?
|
| Proportional Hazards Models | 3 | 2016 | 332 | 0.250 |
Why?
|
| Comorbidity | 3 | 2021 | 457 | 0.250 |
Why?
|
| Severity of Illness Index | 2 | 2021 | 913 | 0.250 |
Why?
|
| Follow-Up Studies | 4 | 2021 | 1689 | 0.230 |
Why?
|
| Delivery of Health Care | 2 | 2023 | 143 | 0.230 |
Why?
|
| Hospital Mortality | 2 | 2015 | 131 | 0.230 |
Why?
|
| Multivariate Analysis | 2 | 2015 | 299 | 0.220 |
Why?
|
| Kidney | 2 | 2023 | 155 | 0.220 |
Why?
|
| Hospitalization | 2 | 2021 | 292 | 0.210 |
Why?
|
| Linezolid | 1 | 2022 | 3 | 0.210 |
Why?
|
| Ganciclovir | 1 | 2022 | 5 | 0.210 |
Why?
|
| Microbial Sensitivity Tests | 1 | 2022 | 75 | 0.200 |
Why?
|
| Drug Resistance, Bacterial | 1 | 2022 | 47 | 0.200 |
Why?
|
| Carbapenems | 1 | 2022 | 39 | 0.200 |
Why?
|
| Benchmarking | 1 | 2022 | 37 | 0.200 |
Why?
|
| Vancomycin | 1 | 2022 | 50 | 0.200 |
Why?
|
| Virus Diseases | 1 | 2022 | 9 | 0.200 |
Why?
|
| Drug Resistance, Multiple, Bacterial | 1 | 2022 | 48 | 0.200 |
Why?
|
| Medicare | 1 | 2022 | 107 | 0.190 |
Why?
|
| Pancreas | 1 | 2021 | 29 | 0.190 |
Why?
|
| Hepatitis C | 1 | 2021 | 44 | 0.180 |
Why?
|
| Forecasting | 1 | 2021 | 92 | 0.180 |
Why?
|
| Adolescent | 2 | 2018 | 2076 | 0.180 |
Why?
|
| Liver Transplantation | 1 | 2021 | 93 | 0.180 |
Why?
|
| HIV-1 | 1 | 2022 | 221 | 0.180 |
Why?
|
| Tertiary Care Centers | 1 | 2020 | 57 | 0.170 |
Why?
|
| Aged, 80 and over | 3 | 2021 | 4459 | 0.170 |
Why?
|
| Insulin | 1 | 2020 | 83 | 0.170 |
Why?
|
| Models, Biological | 1 | 2021 | 311 | 0.160 |
Why?
|
| Meningitis, Cryptococcal | 1 | 2018 | 2 | 0.150 |
Why?
|
| Immunosuppressive Agents | 2 | 2016 | 124 | 0.150 |
Why?
|
| Urinary Tract Infections | 1 | 2017 | 30 | 0.140 |
Why?
|
| Saccharomyces | 1 | 2017 | 1 | 0.140 |
Why?
|
| Idarubicin | 1 | 2017 | 1 | 0.140 |
Why?
|
| Cryptococcus | 1 | 2017 | 3 | 0.140 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 1 | 2017 | 6 | 0.140 |
Why?
|
| Trichosporon | 1 | 2017 | 2 | 0.140 |
Why?
|
| Amphotericin B | 1 | 2017 | 6 | 0.140 |
Why?
|
| Cytarabine | 1 | 2017 | 11 | 0.140 |
Why?
|
| Echinocandins | 1 | 2017 | 5 | 0.140 |
Why?
|
| Vidarabine | 1 | 2017 | 8 | 0.140 |
Why?
|
| Lipopeptides | 1 | 2017 | 9 | 0.140 |
Why?
|
| Voriconazole | 1 | 2017 | 12 | 0.140 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 2017 | 9 | 0.140 |
Why?
|
| Salvage Therapy | 1 | 2017 | 36 | 0.140 |
Why?
|
| Fever | 1 | 2017 | 30 | 0.140 |
Why?
|
| Paecilomyces | 1 | 2016 | 2 | 0.140 |
Why?
|
| Lung Diseases, Fungal | 1 | 2016 | 10 | 0.140 |
Why?
|
| Biopsy | 1 | 2017 | 199 | 0.130 |
Why?
|
| Mycobacterium Infections, Nontuberculous | 1 | 2016 | 6 | 0.130 |
Why?
|
| Dyspnea | 1 | 2016 | 37 | 0.130 |
Why?
|
| Pharmacoepidemiology | 1 | 2016 | 4 | 0.130 |
Why?
|
| Medicare Part D | 1 | 2016 | 6 | 0.130 |
Why?
|
| Kidney Function Tests | 1 | 2016 | 21 | 0.130 |
Why?
|
| Glomerular Filtration Rate | 1 | 2016 | 47 | 0.130 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2017 | 95 | 0.130 |
Why?
|
| Cohort Studies | 2 | 2022 | 1781 | 0.130 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2017 | 222 | 0.120 |
Why?
|
| Florida | 1 | 2014 | 20 | 0.120 |
Why?
|
| California | 1 | 2014 | 30 | 0.120 |
Why?
|
| Income | 1 | 2014 | 78 | 0.110 |
Why?
|
| Prognosis | 1 | 2016 | 739 | 0.110 |
Why?
|
| Residence Characteristics | 1 | 2014 | 183 | 0.100 |
Why?
|
| Pilot Projects | 2 | 2021 | 392 | 0.100 |
Why?
|
| Age Factors | 1 | 2014 | 716 | 0.100 |
Why?
|
| Pneumonia, Staphylococcal | 1 | 2011 | 7 | 0.090 |
Why?
|
| Bacterial Typing Techniques | 1 | 2011 | 10 | 0.090 |
Why?
|
| Molecular Typing | 1 | 2011 | 9 | 0.090 |
Why?
|
| Genotype | 1 | 2011 | 326 | 0.090 |
Why?
|
| Treatment Outcome | 2 | 2016 | 3231 | 0.090 |
Why?
|
| Cerebral Infarction | 1 | 2011 | 142 | 0.090 |
Why?
|
| Astacoidea | 1 | 2009 | 1 | 0.080 |
Why?
|
| Lung Diseases, Parasitic | 1 | 2009 | 1 | 0.080 |
Why?
|
| Paragonimiasis | 1 | 2009 | 1 | 0.080 |
Why?
|
| Paragonimus westermani | 1 | 2009 | 1 | 0.080 |
Why?
|
| Shellfish | 1 | 2009 | 2 | 0.080 |
Why?
|
| Pandemics | 2 | 2022 | 227 | 0.080 |
Why?
|
| Urban Health | 1 | 2006 | 21 | 0.070 |
Why?
|
| Attitude to Health | 1 | 2006 | 90 | 0.060 |
Why?
|
| Patient Compliance | 1 | 2006 | 148 | 0.060 |
Why?
|
| Waiting Lists | 1 | 2023 | 16 | 0.060 |
Why?
|
| Living Donors | 1 | 2023 | 15 | 0.060 |
Why?
|
| Health Facilities | 1 | 2023 | 22 | 0.050 |
Why?
|
| Patients | 1 | 2023 | 32 | 0.050 |
Why?
|
| Proviruses | 1 | 2022 | 3 | 0.050 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2022 | 16 | 0.050 |
Why?
|
| Virus Latency | 1 | 2022 | 15 | 0.050 |
Why?
|
| Data Accuracy | 1 | 2022 | 3 | 0.050 |
Why?
|
| Health Insurance Portability and Accountability Act | 1 | 2022 | 2 | 0.050 |
Why?
|
| Hospitals | 1 | 2022 | 143 | 0.050 |
Why?
|
| Extracorporeal Membrane Oxygenation | 1 | 2021 | 18 | 0.050 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 2021 | 133 | 0.050 |
Why?
|
| Infection Control | 1 | 2022 | 149 | 0.050 |
Why?
|
| Respiration, Artificial | 1 | 2021 | 101 | 0.040 |
Why?
|
| Microbiological Techniques | 1 | 2016 | 5 | 0.030 |
Why?
|
| Recurrence | 1 | 2017 | 275 | 0.030 |
Why?
|
| Microscopy | 1 | 2016 | 10 | 0.030 |
Why?
|
| Prospective Studies | 1 | 2021 | 1633 | 0.030 |
Why?
|
| Radiography, Thoracic | 1 | 2016 | 25 | 0.030 |
Why?
|
| Bronchoscopy | 1 | 2016 | 24 | 0.030 |
Why?
|
| Survival Rate | 1 | 2017 | 308 | 0.030 |
Why?
|
| Midwestern United States | 1 | 2016 | 58 | 0.030 |
Why?
|
| Risk | 1 | 2016 | 190 | 0.030 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2016 | 698 | 0.030 |
Why?
|
| Food Parasitology | 1 | 2009 | 1 | 0.020 |
Why?
|
| Food Contamination | 1 | 2009 | 3 | 0.020 |
Why?
|
| Hemoptysis | 1 | 2009 | 6 | 0.020 |
Why?
|
| Praziquantel | 1 | 2009 | 4 | 0.020 |
Why?
|
| Anthelmintics | 1 | 2009 | 8 | 0.020 |
Why?
|
| Missouri | 1 | 2009 | 24 | 0.020 |
Why?
|
| Tuberculosis | 1 | 2009 | 18 | 0.020 |
Why?
|
| Diagnosis, Differential | 1 | 2009 | 341 | 0.020 |
Why?
|
| Animals | 1 | 2009 | 3510 | 0.010 |
Why?
|